Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tohru Takeuchi

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
International Journal of Molecular Sciences|April 28, 2023
Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by <i>Pneumocystis jirovecii</i> Pneumonia and One-Year Clinical Course: The ANSWER Cohort StudyHideyuki Shiba, Takuya Kotani, Koji Nagai, et al.
Rheumatology (Oxford, England)|June 9, 2026
Comparative effectiveness and safety of sarilumab vs Janus kinase inhibitors in late- and younger-onset rheumatoid arthritisYuji Nozaki, Kazuya Kishimoto, Tetsu Itami, et al.
Rheumatology (Oxford, England)|November 10, 2025
Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in rheumatoid arthritis: the ANSWER cohort studyYuhei Fujisawa, Ryu Watanabe, Tadashi Okano, et al.
Scientific Reports|January 8, 2022
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Arthritis Research & Therapy|January 4, 2026
Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritisYuji Nozaki, Kazuya Kishimoto, Tetsu Itami, et al.
Rheumatology (Oxford, England)|September 5, 2025
Risk prediction model for relapse of anti-synthetase syndrome- associated interstitial lung disease in Japanese multicentre MYKO cohort studyShogo Matsuda, Takuya Kotani, Katsumasa Oe, et al.
Rheumatology (Oxford, England)|October 4, 2023
Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort studyHirotaka Yamada, Sadao Jinno, Toshihisa Maeda, et al.
Annals of the Rheumatic Diseases|April 28, 2026
Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score-matched real-world study accounting for poor prognostic factorsYuji Nozaki, Toshihiko Shiga, Jinhai Ri, et al.
Modern Rheumatology|December 24, 2024
Glucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registryRyo Nishioka, Satoshi Omura, Daiki Nakagomi, et al.
Modern Rheumatology|January 31, 2025
Risk Factors for Cytomegalovirus Reactivation during the Treatment of ANCA-Associated Vasculitis: A retrospective cohort study of the J-CANVAS studyKazutaka Kawamori, Nao Oguro, Kunika Shimizu, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
International Journal of Molecular Sciences|April 28, 2023
Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by <i>Pneumocystis jirovecii</i> Pneumonia and One-Year Clinical Course: The ANSWER Cohort StudyHideyuki Shiba, Takuya Kotani, Koji Nagai, et al.
Rheumatology (Oxford, England)|June 9, 2026
Comparative effectiveness and safety of sarilumab vs Janus kinase inhibitors in late- and younger-onset rheumatoid arthritisYuji Nozaki, Kazuya Kishimoto, Tetsu Itami, et al.
Rheumatology (Oxford, England)|November 10, 2025
Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in rheumatoid arthritis: the ANSWER cohort studyYuhei Fujisawa, Ryu Watanabe, Tadashi Okano, et al.
Scientific Reports|January 8, 2022
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Arthritis Research & Therapy|January 4, 2026
Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritisYuji Nozaki, Kazuya Kishimoto, Tetsu Itami, et al.
Rheumatology (Oxford, England)|September 5, 2025
Risk prediction model for relapse of anti-synthetase syndrome- associated interstitial lung disease in Japanese multicentre MYKO cohort studyShogo Matsuda, Takuya Kotani, Katsumasa Oe, et al.
Rheumatology (Oxford, England)|October 4, 2023
Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort studyHirotaka Yamada, Sadao Jinno, Toshihisa Maeda, et al.
Annals of the Rheumatic Diseases|April 28, 2026
Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score-matched real-world study accounting for poor prognostic factorsYuji Nozaki, Toshihiko Shiga, Jinhai Ri, et al.
Modern Rheumatology|December 24, 2024
Glucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registryRyo Nishioka, Satoshi Omura, Daiki Nakagomi, et al.
Modern Rheumatology|January 31, 2025
Risk Factors for Cytomegalovirus Reactivation during the Treatment of ANCA-Associated Vasculitis: A retrospective cohort study of the J-CANVAS studyKazutaka Kawamori, Nao Oguro, Kunika Shimizu, et al.
Pageof 13